Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A Colao, University of Naples Federico II, Italy
Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly. However, some patients achieve inadequate control of their disease with conventional doses of octreotide LAR or lanreotide Autogel.
A Phase III, multicenter, randomised, parallel-group, three-arm, 24-week study is planned to assess the efficacy of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, as an alternative treatment for these patients. Data from this study is expected to be available sometime next year.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.